By validating CancerHubs predictions we demonstrated that TGOLN2 is a protein with tumour suppressor features in Multiple Myeloma, Breast and Prostate Cancer and that EFTUD2 has an oncogene-like behaviour in Multiple Myeloma. This evidence concerns the gene EFTUD2 and prostate carcinoma.